Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerance of TVB-2640 in Healthy Chinese Subjects
NCT04352361Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of denifanstat in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Ascletis Pharma Inc. Primary endpoint: Adverse events and serious adverse events up to 4 days. Started Apr 2020; status: completed.
02
Drugs
denifanstat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04352361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352361.